02.05.2023 | Original Research
Reducing 25-Hydroxyvitamin D Testing in a Large, Urban Safety Net System
verfasst von:
Hyung J. Cho, MD, Nessreen Mestari, MPA, Sigal Israilov, MD, Da Wi Shin, BE, Komal Chandra, PhD, Daniel Alaiev, BBA, Joseph Talledo, MS, Surafel Tsega, MD, Mariely Garcia, BS, Milana Zaurova, MD, Peter Alarcon Manchego, MD, Mona Krouss, MD
Erschienen in:
Journal of General Internal Medicine
|
Ausgabe 10/2023
Einloggen, um Zugang zu erhalten
Abstract
Background
25-Hydroxyvitamin D testing is increasing
despite national guidelines and Choosing Wisely recommendations against routine screening. Overuse can lead to misdiagnosis and unnecessary downstream testing and treatment. Repeat testing within 3 months is a unique area of overuse.
Objective
To reduce 25-hydroxyvitamin D testing in a large safety net system comprising 11 hospitals and 70 ambulatory centers.
Design
This was a quality improvement initiative with a quasi-experimental interrupted time series design with segmented regression.
Participants
All patients in the inpatient and outpatient settings with at least one order for 25-hydroxyvitamin D were included in the analysis.
Interventions
An electronic health record clinical decision support tool was designed for inpatient and outpatient orders and involved two components: a mandatory prompt requiring appropriate indications and a best practice advisory (BPA) focused on repeat testing within 3 months.
Main Measures
The pre-intervention period (6/17/2020–6/13/2021) was compared to the post-intervention period (6/14/2021–8/28/2022) for total 25-hydroxyvitamin D testing, as well as 3-month repeat testing. Hospital and clinic variation in testing was assessed. Additionally, best practice advisory action rates were analyzed, separated by clinician type and specialty.
Key Results
There were 44% and 46% reductions in inpatient and outpatient orders, respectively (p < 0.001). Inpatient and outpatient 3-month repeat testing decreased by 61% and 48%, respectively (p < 0.001). The best practice advisory true accept rate was 13%.
Conclusion
This initiative successfully reduced 25-hydroxyvitamin D testing through the use of mandatory appropriate indications and a best practice advisory focusing on a unique area of overuse: the repeat testing within a 3-month interval. There was wide variation among hospitals and clinics and variation among clinician types and specialties regarding actions to the best practice advisory.